- Home
- ATXS
as 07-26-2024 4:00pm EST
Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Their second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, or AD, an immune disorder associated with loss of skin barrier function and itching.
| Founded: | 2008 | Country: | United States |
| Employees: | N/A | City: | BOSTON |
| Market Cap: | 525.5M | IPO Year: | 2015 |
| Target Price: | $22.50 | AVG Volume (30 days): | 469.4K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.40 | EPS Growth: | N/A |
| 52 Week Low/High: | $4.26 - $16.90 | Next Earning Date: | 08-05-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Astria Therapeutics Inc. (ATXS)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Morabito Christopher | ATXS | Chief Medical Officer | Apr 1 '24 | Sell | $13.59 | 10,000 | $135,939.00 | 0 | SEC Form 4 |
| PERCEPTIVE ADVISORS LLC | ATXS | Director | Feb 1 '24 | Buy | $12.09 | 2,481,350 | $29,999,521.50 | 4,873,721 | SEC Form 4 |
| Morabito Christopher | ATXS | Chief Medical Officer | Jan 26 '24 | Sell | $11.02 | 800 | $8,812.00 | 0 | SEC Form 4 |
| Morabito Christopher | ATXS | Chief Medical Officer | Jan 26 '24 | Sell | $11.15 | 9,200 | $102,552.40 | 0 | SEC Form 4 |
Latest Astria Therapeutics Inc. News
ATXS Breaking Stock News: Dive into ATXS Ticker-Specific Updates for Smart Investing
Business Wire
24 days ago
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PR Newswire
2 months ago
NexTech Solutions Has Agreed to Acquire Rome Research Corporation to Expand Service Offerings and Enhance Mission Support Capabilities
Business Wire
2 months ago
Form 8.3 - International Distribution Services plc
Business Wire
2 months ago
Form 8.3 - Darktrace plc
Reuters
2 months ago
US Supreme Court rejects Kroger challenge to Grubhub trademark win
Investor's Business Daily
2 months ago
Dow Jones Falls As AMD Slides On Downgrade; Nvidia Stock Split Takes Effect
Business Wire
2 months ago
GoldATM Supports Growing Consumer Demand for Gold Purchase with New ATMs in North Carolina
GlobeNewswire
2 months ago
Middlefield Canadian Income PCC: Net Asset Value(s)
Compare ATXS vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ATXS Astria Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.